NCT02365597 2026-03-19
An Efficacy and Safety Study of Erdafitinib (JNJ-42756493) in Participants With Urothelial Cancer
Janssen Research & Development, LLC
Phase 2 Active not recruiting
Janssen Research & Development, LLC
National Cancer Institute (NCI)
Dana-Farber Cancer Institute
Alliance for Clinical Trials in Oncology